Fundraising Fox

bioAffinity Technologies

NASDAQ: BIAF

San Anonio, US · Founded 2014 · Delaware corporation

bioaffinitytech.com
Biotech

Founders & leadership

MZ
Maria ZannesChief Executive Officer
VR
Vivienne RebelChief Science and Medical Officer
XR
Xavier RevelesChief Operating Officer
TP
Timothy P. ZannesExecutive VP and Secretary
MD
Michael DoughertyChief Financial Officer
MH
Myron HolubiakDirector
BF
Barry FrankelDirector
GR
Gary RubinDirector
JP
Jamie PlattDirector
PK
Peter KnightDirector
SD
Stuart DiamondDirector
RJ
Roby JoyceDirector

Competitors · 8

by search overlap

Companies competing with bioAffinity Technologies for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
$4MofferedOct 2024 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart DiamondDirector
  • Vivienne RebelExecutive Officer
  • Xavier RevelesExecutive Officer
  • James EdwardsExecutive Officer
  • Robert AndersonDirector
  • Maria ZannesExecutive Officer, Director
  • Steven GirgentiExecutive Officer, Director
  • Roby JoyceDirector
  • Jamie PlattDirector
  • Peter S. KnightDirector
  • Gary RubinDirector
  • Timothy P. ZannesExecutive Officer
Offering amount
$4M
Sales commissions
$213K
Placement agents
Wallachbeth Capital LLC
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$450KraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gary RubinDirector
  • Maria ZannesExecutive Officer, Director
  • Roby JoyceDirector
  • Robert A. AndersonDirector
  • Jamie PlattDirector
  • Xavier RevelesExecutive Officer
  • Stuart DiamondDirector
  • Michael DoughertyExecutive Officer
  • Peter KnightDirector
  • Timothy P. ZannesExecutive Officer
  • Vivienne RebelExecutive Officer
  • Steven GirgentiDirector
Offering amount
$450K
Amount sold
$450K
Sales commissions
$36K
Placement agents
WallachBeth Capital LLC
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$1.3MraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vivienne RebelExecutive Officer
  • Gary RubinDirector
  • Xavier RevelesExecutive Officer, Director
  • Jamie PlattDirector
  • Maria ZannesExecutive Officer, Director
  • Peter KnightDirector
  • Stuart DiamondDirector
  • Roby JoyceDirector
  • Robert A. AndersonDirector
  • Steven GirgentiDirector
  • Timothy P. ZannesExecutive Officer
  • Michael DoughertyExecutive Officer
Offering amount
$1.3M
Amount sold
$1.3M
Sales commissions
$104.2K
Placement agents
WallachBeth Capital LLC
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2.6MraisedMar 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roby JoyceDirector
  • Maria ZannesExecutive Officer, Director
  • Vivienne RebelExecutive Officer
  • Michael DoughertyExecutive Officer
  • Jamie PlattDirector
  • Timothy P. ZannesExecutive Officer
  • Steven GirgentiExecutive Officer, Director
Offering amount
$2.6M
Amount sold
$2.6M
Minimum investment
$2.6M
Sales commissions
$225K
Placement agents
WallachBeth Capital LLC
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$4MraisedJul 2017 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Myron HolubiakDirector
  • Barry FrankelDirector
  • Steven GirgentiDirector
  • Maria ZannesExecutive Officer, Director
  • Robert AndersonDirector
Offering amount
$4M
Amount sold
$4M
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.